CDK8/19 Mediator kinases potentiate induction of transcription by NFκB

Mengqian Chen, Jiaxin Liang, Hao Ji, Zhengguan Yang, Serena Altilia, Bing Hu, Adam Schronce, Martina S.J. McDermott, Gary P. Schools, Chang Uk Lim, David Oliver, Michael S. Shtutman, Tao Lu, George R. Stark, Donald C. Porter, Eugenia V. Broude, Igor B. Roninson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The nuclear factor-κB (NFκB) family of transcription factors has been implicated in inflammatory disorders, viral infections, and cancer. Most of the drugs that inhibit NFκB show significant side effects, possibly due to sustained NFκB suppression. Drugs affecting induced, but not basal, NFκB activity may have the potential to provide therapeutic benefit without associated toxicity. NFκB activation by stress-inducible cell cycle inhibitor p21 was shown to be mediated by a p21-stimulated transcription-regulating kinase CDK8. CDK8 and its paralog CDK19, associated with the transcriptional Mediator complex, act as coregulators of several transcription factors implicated in cancer; CDK8/19 inhibitors are entering clinical development. Here we show that CDK8/19 inhibition by different small-molecule kinase inhibitors or shRNAs suppresses the elongation of NFκB-induced transcription when such transcription is activated by p21-independent canonical inducers, such as TNFα. On NFκB activation, CDK8/19 are corecruited with NFκB to the promoters of the responsive genes. Inhibition of CDK8/19 kinase activity suppresses the RNA polymerase II C-terminal domain phosphorylation required for transcriptional elongation, in a gene-specific manner. Genes coregulated by CDK8/19 and NFκB include IL8, CXCL1, and CXCL2, which encode tumor-promoting proinflammatory cytokines. Although it suppressed newly induced NFκB-driven transcription, CDK8/19 inhibition in most cases had no effect on the basal expression of NFκB-regulated genes or promoters; the same selective regulation of newly induced transcription was observed with other transcription signals potenti-ated by CDK8/19. This selective role of CDK8/19 identifies these kinases as mediators of transcriptional reprogramming, a key aspect of development and differentiation as well as pathological processes.

Original languageEnglish (US)
Pages (from-to)10208-10213
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume114
Issue number38
DOIs
StatePublished - Sep 19 2017

Fingerprint

Transcription Factors
Phosphotransferases
Genes
Mediator Complex
RNA Polymerase III
Peptide Elongation Factors
Neoplasms
RNA Polymerase II
Virus Diseases
Pathologic Processes
Interleukin-8
Pharmaceutical Preparations
Cell Cycle
Phosphorylation
Cytokines
Therapeutics

Keywords

  • CDK19
  • CDK8
  • NFκB
  • Regulation of transcription
  • RNA polymerase II

ASJC Scopus subject areas

  • General

Cite this

CDK8/19 Mediator kinases potentiate induction of transcription by NFκB. / Chen, Mengqian; Liang, Jiaxin; Ji, Hao; Yang, Zhengguan; Altilia, Serena; Hu, Bing; Schronce, Adam; McDermott, Martina S.J.; Schools, Gary P.; Lim, Chang Uk; Oliver, David; Shtutman, Michael S.; Lu, Tao; Stark, George R.; Porter, Donald C.; Broude, Eugenia V.; Roninson, Igor B.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, No. 38, 19.09.2017, p. 10208-10213.

Research output: Contribution to journalArticle

Chen, M, Liang, J, Ji, H, Yang, Z, Altilia, S, Hu, B, Schronce, A, McDermott, MSJ, Schools, GP, Lim, CU, Oliver, D, Shtutman, MS, Lu, T, Stark, GR, Porter, DC, Broude, EV & Roninson, IB 2017, 'CDK8/19 Mediator kinases potentiate induction of transcription by NFκB', Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 38, pp. 10208-10213. https://doi.org/10.1073/pnas.1710467114
Chen, Mengqian ; Liang, Jiaxin ; Ji, Hao ; Yang, Zhengguan ; Altilia, Serena ; Hu, Bing ; Schronce, Adam ; McDermott, Martina S.J. ; Schools, Gary P. ; Lim, Chang Uk ; Oliver, David ; Shtutman, Michael S. ; Lu, Tao ; Stark, George R. ; Porter, Donald C. ; Broude, Eugenia V. ; Roninson, Igor B. / CDK8/19 Mediator kinases potentiate induction of transcription by NFκB. In: Proceedings of the National Academy of Sciences of the United States of America. 2017 ; Vol. 114, No. 38. pp. 10208-10213.
@article{6a6d281743e549beaeb21e420d6b084f,
title = "CDK8/19 Mediator kinases potentiate induction of transcription by NFκB",
abstract = "The nuclear factor-κB (NFκB) family of transcription factors has been implicated in inflammatory disorders, viral infections, and cancer. Most of the drugs that inhibit NFκB show significant side effects, possibly due to sustained NFκB suppression. Drugs affecting induced, but not basal, NFκB activity may have the potential to provide therapeutic benefit without associated toxicity. NFκB activation by stress-inducible cell cycle inhibitor p21 was shown to be mediated by a p21-stimulated transcription-regulating kinase CDK8. CDK8 and its paralog CDK19, associated with the transcriptional Mediator complex, act as coregulators of several transcription factors implicated in cancer; CDK8/19 inhibitors are entering clinical development. Here we show that CDK8/19 inhibition by different small-molecule kinase inhibitors or shRNAs suppresses the elongation of NFκB-induced transcription when such transcription is activated by p21-independent canonical inducers, such as TNFα. On NFκB activation, CDK8/19 are corecruited with NFκB to the promoters of the responsive genes. Inhibition of CDK8/19 kinase activity suppresses the RNA polymerase II C-terminal domain phosphorylation required for transcriptional elongation, in a gene-specific manner. Genes coregulated by CDK8/19 and NFκB include IL8, CXCL1, and CXCL2, which encode tumor-promoting proinflammatory cytokines. Although it suppressed newly induced NFκB-driven transcription, CDK8/19 inhibition in most cases had no effect on the basal expression of NFκB-regulated genes or promoters; the same selective regulation of newly induced transcription was observed with other transcription signals potenti-ated by CDK8/19. This selective role of CDK8/19 identifies these kinases as mediators of transcriptional reprogramming, a key aspect of development and differentiation as well as pathological processes.",
keywords = "CDK19, CDK8, NFκB, Regulation of transcription, RNA polymerase II",
author = "Mengqian Chen and Jiaxin Liang and Hao Ji and Zhengguan Yang and Serena Altilia and Bing Hu and Adam Schronce and McDermott, {Martina S.J.} and Schools, {Gary P.} and Lim, {Chang Uk} and David Oliver and Shtutman, {Michael S.} and Tao Lu and Stark, {George R.} and Porter, {Donald C.} and Broude, {Eugenia V.} and Roninson, {Igor B.}",
year = "2017",
month = "9",
day = "19",
doi = "10.1073/pnas.1710467114",
language = "English (US)",
volume = "114",
pages = "10208--10213",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "38",

}

TY - JOUR

T1 - CDK8/19 Mediator kinases potentiate induction of transcription by NFκB

AU - Chen, Mengqian

AU - Liang, Jiaxin

AU - Ji, Hao

AU - Yang, Zhengguan

AU - Altilia, Serena

AU - Hu, Bing

AU - Schronce, Adam

AU - McDermott, Martina S.J.

AU - Schools, Gary P.

AU - Lim, Chang Uk

AU - Oliver, David

AU - Shtutman, Michael S.

AU - Lu, Tao

AU - Stark, George R.

AU - Porter, Donald C.

AU - Broude, Eugenia V.

AU - Roninson, Igor B.

PY - 2017/9/19

Y1 - 2017/9/19

N2 - The nuclear factor-κB (NFκB) family of transcription factors has been implicated in inflammatory disorders, viral infections, and cancer. Most of the drugs that inhibit NFκB show significant side effects, possibly due to sustained NFκB suppression. Drugs affecting induced, but not basal, NFκB activity may have the potential to provide therapeutic benefit without associated toxicity. NFκB activation by stress-inducible cell cycle inhibitor p21 was shown to be mediated by a p21-stimulated transcription-regulating kinase CDK8. CDK8 and its paralog CDK19, associated with the transcriptional Mediator complex, act as coregulators of several transcription factors implicated in cancer; CDK8/19 inhibitors are entering clinical development. Here we show that CDK8/19 inhibition by different small-molecule kinase inhibitors or shRNAs suppresses the elongation of NFκB-induced transcription when such transcription is activated by p21-independent canonical inducers, such as TNFα. On NFκB activation, CDK8/19 are corecruited with NFκB to the promoters of the responsive genes. Inhibition of CDK8/19 kinase activity suppresses the RNA polymerase II C-terminal domain phosphorylation required for transcriptional elongation, in a gene-specific manner. Genes coregulated by CDK8/19 and NFκB include IL8, CXCL1, and CXCL2, which encode tumor-promoting proinflammatory cytokines. Although it suppressed newly induced NFκB-driven transcription, CDK8/19 inhibition in most cases had no effect on the basal expression of NFκB-regulated genes or promoters; the same selective regulation of newly induced transcription was observed with other transcription signals potenti-ated by CDK8/19. This selective role of CDK8/19 identifies these kinases as mediators of transcriptional reprogramming, a key aspect of development and differentiation as well as pathological processes.

AB - The nuclear factor-κB (NFκB) family of transcription factors has been implicated in inflammatory disorders, viral infections, and cancer. Most of the drugs that inhibit NFκB show significant side effects, possibly due to sustained NFκB suppression. Drugs affecting induced, but not basal, NFκB activity may have the potential to provide therapeutic benefit without associated toxicity. NFκB activation by stress-inducible cell cycle inhibitor p21 was shown to be mediated by a p21-stimulated transcription-regulating kinase CDK8. CDK8 and its paralog CDK19, associated with the transcriptional Mediator complex, act as coregulators of several transcription factors implicated in cancer; CDK8/19 inhibitors are entering clinical development. Here we show that CDK8/19 inhibition by different small-molecule kinase inhibitors or shRNAs suppresses the elongation of NFκB-induced transcription when such transcription is activated by p21-independent canonical inducers, such as TNFα. On NFκB activation, CDK8/19 are corecruited with NFκB to the promoters of the responsive genes. Inhibition of CDK8/19 kinase activity suppresses the RNA polymerase II C-terminal domain phosphorylation required for transcriptional elongation, in a gene-specific manner. Genes coregulated by CDK8/19 and NFκB include IL8, CXCL1, and CXCL2, which encode tumor-promoting proinflammatory cytokines. Although it suppressed newly induced NFκB-driven transcription, CDK8/19 inhibition in most cases had no effect on the basal expression of NFκB-regulated genes or promoters; the same selective regulation of newly induced transcription was observed with other transcription signals potenti-ated by CDK8/19. This selective role of CDK8/19 identifies these kinases as mediators of transcriptional reprogramming, a key aspect of development and differentiation as well as pathological processes.

KW - CDK19

KW - CDK8

KW - NFκB

KW - Regulation of transcription

KW - RNA polymerase II

UR - http://www.scopus.com/inward/record.url?scp=85029560150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029560150&partnerID=8YFLogxK

U2 - 10.1073/pnas.1710467114

DO - 10.1073/pnas.1710467114

M3 - Article

C2 - 28855340

AN - SCOPUS:85029560150

VL - 114

SP - 10208

EP - 10213

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 38

ER -